BETHESDA, Md.--(BUSINESS WIRE)--
TNI BioTech, Inc. (OTCQB:finance.yahoo.com%2Fq%3Fs%3Dtnib&esheet=50706673&newsitemid=20130911005267&lan=en-US&anchor=TNIB&index=1&md5=858b799fc14995b1af248833344de07c" rel="nofollow">TNIB)
and Laboratorios Ramos announced today that they entered a manufacturing
and supply agreement for the production of Low Dose Naltrexone (“LDN”)
for commercial use. This agreement enables TNIB to focus on the
development and commercialization of therapeutic treatments for cancer,
HIV/AIDS and autoimmune diseases by combating these fatal diseases
through the activation and modulation of the body’s immune system. Under
the agreement, TNIB and Laboratorios Ramos are responsible for the
technology transfer, under a manufacturing agreement, and commercial
production of LDN at the Laboratorios Ramos processing facility.
Laboratorios Ramos operates "under the principles of the ICH" for cGMP
and currently produces commercial products for sale in Nicaragua. The
financial terms of the agreement have not been disclosed.
“Laboratorios Ramos is pleased to establish this collaboration with TNIB
on the commercial production of LDN,” stated a representative from
Laboratorios Ramos. “We look forward to leveraging our experience with
production to ensure the rapid commercial launch of this important
“This manufacturing agreement with Laboratorios Ramos is an important
operational milestone taking us one step closer to the commercial
introduction of LDN later this year," said Noreen Griffin Chief
Executive Officer of TNIB. "We believe Laboratorios Ramos is the right
manufacturing partner for TNIB and the agreement allows TNI BioTech to
move the product forward in the most cost effective way.” Management
believes the Laboratorios Ramos facility is well suited to supply
commercial quantities of LDN. The multi-purpose finished product
processing facility houses production clean rooms with a broad range of
formulation and packaging equipment to meet all requirements for
commercial production of LDN.
TNI BioTech has received a capital investment of $1,360,625.00 from
the conversion existing warrants by our shareholders. The Company
believes that other warrant holders will convert and provide the company
with additional capital between $250,000 to $500,000 in the coming month.
About TNI BioTech, Inc.
TNI BioTech, Inc. is a biotech company working to combat chronic,
life-threatening diseases through the activation and modulation of the
body's immune system using our patented immunotherapy. Our products and
immunotherapy technologies are designed to harness the power of the
immune system to improve the treatment of cancer, infections such as
HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.